Long-term analysis shows declining vision-related quality of life after second eye treatment in nAMD, suggesting need for support.
Long-term VRQoL remains stable in unilateral treated nAMD. However, a clinically meaningful reduction in VRQoL occurs following development and treatment in the second eye which does not recover. It is important to offer appropriate support when the first and then second eye develop nAMD.
No takes yet. Share an insight, caveat, or question.
Airody et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: